Logo

BMEA

Biomea Fusion, Inc.

BMEA

Biomea Fusion, Inc. • NASDAQ
$1.08 ▲ 1.40% (+0.01)
Market Cap $64.55 M
52w High $7.46
52w Low $0.87
Dividend Yield 0%
P/E -0.48
Volume 691.56K
Outstanding Shares 59.50M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $20.805M ▲ $-16.407M ▲ 0% $-0.27 ▲ $-15.98M ▲
Q2-2025 $0 $20.776M ▼ $-20.74M ▲ 0% $-0.51 ▲ $-20.24M ▲
Q1-2025 $0 $29.712M ▼ $-29.262M ▲ 0% $-0.8 ▲ $-29.244M ▲
Q4-2024 $0 $30.074M ▼ $-29.302M ▲ 0% $-0.81 ▲ $-29.605M ▲
Q3-2024 $0 $34.039M $-32.787M 0% $-0.91 $-33.603M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $46.642M ▼ $55.187M ▼ $39.568M ▼ $15.619M ▼
Q2-2025 $56.224M ▲ $73.163M ▲ $45.653M ▲ $27.51M ▼
Q1-2025 $35.864M ▼ $55.055M ▼ $26.318M ▼ $28.737M ▼
Q4-2024 $58.279M ▼ $79.938M ▼ $28.365M ▼ $51.573M ▼
Q3-2024 $87.952M $110.419M $34.447M $75.972M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-16.407M ▲ $-12.178M ▲ $0 $2.596M ▼ $-9.582M ▼ $-12.178M ▲
Q2-2025 $-20.74M ▲ $-19.212M ▲ $0 $39.572M ▲ $20.36M ▲ $-19.212M ▲
Q1-2025 $-29.262M ▲ $-25.667M ▲ $0 ▲ $3.252M ▲ $-22.415M ▲ $-25.667M ▲
Q4-2024 $-29.302M ▲ $-30.004M ▼ $-82K ▲ $413K ▲ $-29.673M ▼ $-30.086M ▼
Q3-2024 $-32.787M $-25.217M $-186K $69K $-25.334M $-25.403M

Five-Year Company Overview

Income Statement

Income Statement Biomea Fusion is still a classic early‑stage biotech story: there is no product revenue yet, so the income statement is entirely driven by research and development and other operating costs. Losses have grown steadily over the past several years as the company has moved its lead programs further into the clinic. Per‑share losses have also become larger over time, reflecting both higher spending and the dilution that typically comes with financing a pipeline. This pattern is normal for a development‑stage biotech but means the business is currently dependent on external funding rather than internal profit generation.

Balance Sheet

Balance Sheet The balance sheet is dominated by cash and short‑term investments, with only a small amount of other assets and very limited debt. Cash levels swelled after the IPO and have since declined as the company funds its trials, but cash still represents the core of its asset base. Shareholders’ equity rose as capital was raised, then has been eroded by ongoing losses. Overall, the company appears light on fixed obligations but reliant on its cash reserves and future capital access to support ongoing development.

Cash Flow

Cash Flow Cash flow is negative and driven almost entirely by operating activities, mainly research and development and related overhead. There is essentially no spending on large physical assets, so free cash flow is almost the same as operating cash flow, and both are clearly in the red. The cash “burn” has increased over time as programs advance, which is typical but underscores the need for either additional financing, partnerships, or cost controls to extend the runway once current cash is used.

Competitive Edge

Competitive Edge Biomea occupies a focused niche within metabolic disease, aiming at diabetes and obesity with a distinct covalent chemistry platform. Its lead diabetes candidate targets regeneration of insulin‑producing cells rather than just blood sugar control, which, if validated, would be highly differentiated. At the same time, the company faces very intense competition: large pharmaceutical firms dominate diabetes and obesity, and other players are pursuing similar biological targets and oral GLP‑1 approaches. Biomea’s edge rests on being scientifically differentiated and potentially complementary to existing drugs, but it must prove this in larger, longer clinical trials while competing for attention and resources in a crowded field.

Innovation and R&D

Innovation and R&D Innovation is the heart of Biomea’s story. The proprietary FUSION discovery system and focus on covalent small molecules give it a clear scientific identity. The shift away from oncology to concentrate on metabolic disease has created a more focused R&D strategy, with two main pillars: the menin inhibitor icovamenib for diabetes and an oral GLP‑1 candidate for obesity. Early data on icovamenib, including durability after treatment stops, is encouraging but still preliminary. Future milestones—longer‑term diabetes data, combination studies with GLP‑1 drugs, progress in type 1 diabetes, and the first clinical steps for the obesity program—will heavily influence how the R&D story is perceived. As with any early‑stage biotech, there is substantial clinical, regulatory, and execution risk alongside the scientific upside.

Summary

Biomea Fusion is a high‑risk, high‑uncertainty development‑stage biotech built around a distinctive covalent chemistry platform and an ambitious goal: disease‑modifying treatments for diabetes and, eventually, obesity. Financially, it has no revenue, growing losses, and negative cash flow, and it depends on its cash reserves and future funding to advance its pipeline. Strategically, it offers a differentiated scientific angle in a very large market, but it operates against powerful, well‑funded competitors and faces the usual binary nature of clinical trial outcomes. How effectively the company can manage its cash burn, secure partnerships or additional capital, and deliver convincing clinical data over the next couple of years will largely determine its longer‑term position and options.

NEWS

November 24, 2025 · 7:00 AM UTC

Biomea Fusion to Participate at Upcoming Investor Conferences

Read more

November 10, 2025 · 7:00 AM UTC

Biomea Fusion to Participate at Jefferies London Healthcare Conference

Read more

November 5, 2025 · 7:00 AM UTC

Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025

Read more

November 4, 2025 · 4:05 PM UTC

Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights

Read more

October 30, 2025 · 8:00 AM UTC

Biomea Fusion to Present Poster Presentations at ObesityWeek®2025

Read more